Research programme: multiple sclerosis therapeutic - MultiCell Technologies
Alternative Names: MCT-165; MCT-175Latest Information Update: 14 Mar 2011
At a glance
- Originator MultiCell Technologies Inc
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators; MHC class II gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 14 Mar 2011 No development reported - Preclinical for Multiple sclerosis in USA (Injection)
- 09 Jan 2006 Preclinical trials in Multiple sclerosis in USA (unspecified route)